These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26059720)

  • 41. Monogenic autoinflammatory diseases.
    Russo RA; Brogan PA
    Rheumatology (Oxford); 2014 Nov; 53(11):1927-39. PubMed ID: 24831056
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autoinflammatory diseases: update on classification diagnosis and management.
    Pathak S; McDermott MF; Savic S
    J Clin Pathol; 2017 Jan; 70(1):1-8. PubMed ID: 27646526
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Type 2 diabetes mellitus: a metabolic autoinflammatory disease.
    Mandrup-Poulsen T
    Dermatol Clin; 2013 Jul; 31(3):495-506. PubMed ID: 23827251
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interleukin-1: Ariadne's Thread in Autoinflammatory and Autoimmune Disorders.
    Cantarini L; Lopalco G; Cattalini M; Vitale A; Galeazzi M; Rigante D
    Isr Med Assoc J; 2015 Feb; 17(2):93-7. PubMed ID: 26223084
    [TBL] [Abstract][Full Text] [Related]  

  • 45. No shortcuts: new findings reinforce why nuance is the rule in genetic autoinflammatory syndromes.
    Tsoukas P; Canna SW
    Curr Opin Rheumatol; 2017 Sep; 29(5):506-515. PubMed ID: 28604422
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of biological agents in immune-mediated inflammatory diseases.
    Efthimiou P; Markenson JA
    South Med J; 2005 Feb; 98(2):192-204. PubMed ID: 15759950
    [TBL] [Abstract][Full Text] [Related]  

  • 47. IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting.
    Broderick L; Hoffman HM
    Nat Rev Rheumatol; 2022 Aug; 18(8):448-463. PubMed ID: 35729334
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].
    Varisco PA; So A
    Rev Med Suisse; 2014 Jan; 10(414):187-91. PubMed ID: 24624736
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An analysis of FDA-approved drugs for inflammation and autoimmune diseases.
    Kinch MS; Merkel J
    Drug Discov Today; 2015 Aug; 20(8):920-3. PubMed ID: 25701283
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Relationship between NALP3 and Autoinflammatory Syndromes.
    Campbell L; Raheem I; Malemud CJ; Askari AD
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27187378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Potential cardiovascular implications of Janus kinase inhibitors in immune mediated diseases.
    Mehta NN
    Cardiovasc Res; 2018 Sep; 114(11):e81-e83. PubMed ID: 30428019
    [No Abstract]   [Full Text] [Related]  

  • 52. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo.
    Tanimoto A; Ogawa Y; Oki C; Kimoto Y; Nozawa K; Amano W; Noji S; Shiozaki M; Matsuo A; Shinozaki Y; Matsushita M
    Inflamm Res; 2015 Jan; 64(1):41-51. PubMed ID: 25387665
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Autoinflammatory diseases in dermatology: CAPS, TRAPS, HIDS, FMF, Blau, CANDLE.
    Tripathi SV; Leslie KS
    Dermatol Clin; 2013 Jul; 31(3):387-404. PubMed ID: 23827243
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Working the endless puzzle of hereditary autoinflammatory disorders.
    Caso F; Cantarini L; Lucherini OM; Sfriso P; Fioretti M; Costa L; Vitale A; Atteno M; Galeazzi M; Muscari I; Magnotti F; Frediani B; Punzi L; Rigante D
    Mod Rheumatol; 2014 May; 24(3):381-9. PubMed ID: 24251993
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.
    Brennan FR; Cauvin A; Tibbitts J; Wolfreys A
    Drug Dev Res; 2014 May; 75(3):115-61. PubMed ID: 24782266
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Emerging approaches for the therapy of autoimmune and chronic inflammatory disease.
    Cope AP; Feldmann M
    Curr Opin Immunol; 2004 Dec; 16(6):780-6. PubMed ID: 15511673
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potential target of infliximab in autoimmune and inflammatory diseases.
    Atzeni F; Doria A; Carrabba M; Turiel M; Sarzi-Puttini P
    Autoimmun Rev; 2007 Sep; 6(8):529-36. PubMed ID: 17854744
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The immunomodulatory and anti-inflammatory properties of different antimicrobial agents].
    Guz K; Bugla-Płoskońska G
    Postepy Hig Med Dosw (Online); 2007 Dec; 61():828-37. PubMed ID: 18097341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. XToll, a recombinant chaperonin 10 as an anti-inflammatory immunomodulator.
    van Eden W
    Curr Opin Investig Drugs; 2008 May; 9(5):523-33. PubMed ID: 18465663
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives.
    Cantarini L; Lucherini OM; Muscari I; Frediani B; Galeazzi M; Brizi MG; Simonini G; Cimaz R
    Autoimmun Rev; 2012 Nov; 12(1):38-43. PubMed ID: 22884554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.